Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival
- PMID: 9516978
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival
Abstract
We have determined the expression of transforming growth factor alpha (TGF alpha), amphiregulin (AR), CRIPTO, the epidermal growth factor receptor (EGFR), erbB-2, erbB-3, and tumor angiogenesis in a series of 195 patients with stage I-IIIA non-small cell lung cancer (NSCLC) treated with radical surgery to define their usefulness as prognostic indicators of survival. A variable degree of specific staining in cancer cells was observed for the three growth factors and for the three growth factor receptors in the majority of NSCLC patients. A statistically significant association between overexpression of TGF alpha, AR, and CRIPTO was observed. Enhanced expression of AR was significantly correlated with enhanced expression of erbB-2 and advanced T-stage. A direct association was also detected for overexpression of TGF alpha and of erbB-2 or erbB-3, respectively. Sex, tumor size, nodal status, stage, microvessel count, as a measure of neovascularization, and AR overexpression significantly correlated with overall survival at univariate analysis. In a Cox multivariate analysis, the only characteristics with an independent prognostic effect on OAS were microvessel count [relative hazard (RH), 6.61; P < 0.00001), nodal status (RH, 1.59; P = 0.0013), and AR overexpression (RH, 1.72; P = 0.02). These results suggest that evaluation of neoangiogenesis and of certain growth factors, such as AR, can be useful in addition to conventional pathological staging to select high-risk NSCLC patients who may benefit from post-surgical systemic therapies.
Similar articles
-
Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.Lung Cancer. 2006 Feb;51(2):143-58. doi: 10.1016/j.lungcan.2005.09.005. Epub 2005 Dec 19. Lung Cancer. 2006. PMID: 16360975 Review.
-
Prognostic factors in stage I/II non-small cell lung cancer.Lung Cancer. 2001 Sep;33 Suppl 1:S17-24. doi: 10.1016/s0169-5002(01)00298-7. Lung Cancer. 2001. PMID: 11576703 Review.
-
Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization.Br J Cancer. 2000 Aug;83(4):480-6. doi: 10.1054/bjoc.2000.1345. Br J Cancer. 2000. PMID: 10945495 Free PMC article.
-
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.Clin Cancer Res. 1997 Apr;3(4):515-22. Clin Cancer Res. 1997. PMID: 9815714
-
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.Cancer Res. 1993 May 15;53(10 Suppl):2379-85. Cancer Res. 1993. PMID: 7683573
Cited by
-
Anticancer Evaluation of Novel Benzofuran-Indole Hybrids as Epidermal Growth Factor Receptor Inhibitors against Non-Small-Cell Lung Cancer Cells.Pharmaceuticals (Basel). 2024 Feb 9;17(2):231. doi: 10.3390/ph17020231. Pharmaceuticals (Basel). 2024. PMID: 38399447 Free PMC article.
-
Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase.Front Pharmacol. 2024 Jan 11;14:1231671. doi: 10.3389/fphar.2023.1231671. eCollection 2023. Front Pharmacol. 2024. PMID: 38273823 Free PMC article.
-
Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers.iScience. 2023 Jan 31;26(3):106082. doi: 10.1016/j.isci.2023.106082. eCollection 2023 Mar 17. iScience. 2023. PMID: 36852277 Free PMC article.
-
Changes in HER3 expression profiles between primary and recurrent gynecological cancers.Cancer Cell Int. 2023 Feb 3;23(1):18. doi: 10.1186/s12935-022-02844-z. Cancer Cell Int. 2023. PMID: 36737733 Free PMC article.
-
Advanced Lab-on-Fiber Optrodes Assisted by Oriented Antibody Immobilization Strategy.Biosensors (Basel). 2022 Nov 17;12(11):1040. doi: 10.3390/bios12111040. Biosensors (Basel). 2022. PMID: 36421158 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous